Robeco Institutional Asset Management B.V. Purchases 350,026 Shares of Exelixis, Inc. (NASDAQ:EXEL)

Robeco Institutional Asset Management B.V. lifted its stake in shares of Exelixis, Inc. (NASDAQ:EXEL - Free Report) by 263.1% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 483,064 shares of the biotechnology company's stock after acquiring an additional 350,026 shares during the period. Robeco Institutional Asset Management B.V. owned 0.17% of Exelixis worth $12,536,000 as of its most recent SEC filing.

Other institutional investors have also recently added to or reduced their stakes in the company. Mirae Asset Global Investments Co. Ltd. grew its position in Exelixis by 3.8% during the first quarter. Mirae Asset Global Investments Co. Ltd. now owns 35,771 shares of the biotechnology company's stock valued at $778,000 after acquiring an additional 1,301 shares during the period. Janney Montgomery Scott LLC grew its holdings in shares of Exelixis by 6.1% during the first quarter. Janney Montgomery Scott LLC now owns 60,746 shares of the biotechnology company's stock valued at $1,442,000 after purchasing an additional 3,510 shares during the last quarter. Nordea Investment Management AB increased its stake in shares of Exelixis by 17.3% in the first quarter. Nordea Investment Management AB now owns 202,292 shares of the biotechnology company's stock valued at $4,835,000 after purchasing an additional 29,784 shares during the period. LSV Asset Management lifted its position in Exelixis by 1,651.4% in the first quarter. LSV Asset Management now owns 2,774,707 shares of the biotechnology company's stock worth $65,844,000 after purchasing an additional 2,616,278 shares during the period. Finally, Susquehanna Fundamental Investments LLC acquired a new position in shares of Exelixis in the 1st quarter valued at $10,906,000. Institutional investors and hedge funds own 85.27% of the company's stock.

Insider Buying and Selling at Exelixis

In other news, EVP Dana Aftab sold 20,883 shares of the stock in a transaction on Monday, August 12th. The stock was sold at an average price of $27.06, for a total transaction of $565,093.98. Following the completion of the transaction, the executive vice president now directly owns 500,107 shares in the company, valued at approximately $13,532,895.42. This represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. In related news, EVP Dana Aftab sold 20,883 shares of the company's stock in a transaction that occurred on Monday, August 12th. The stock was sold at an average price of $27.06, for a total value of $565,093.98. Following the sale, the executive vice president now owns 500,107 shares in the company, valued at $13,532,895.42. This represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, EVP Jeffrey Hessekiel sold 20,000 shares of Exelixis stock in a transaction on Monday, August 26th. The shares were sold at an average price of $25.79, for a total transaction of $515,800.00. Following the transaction, the executive vice president now owns 630,325 shares in the company, valued at $16,256,081.75. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 305,295 shares of company stock valued at $8,831,001. Corporate insiders own 2.85% of the company's stock.

Exelixis Stock Performance

Exelixis stock traded up $0.45 during trading hours on Thursday, hitting $35.96. The company had a trading volume of 1,003,691 shares, compared to its average volume of 2,073,136. The firm has a market cap of $10.27 billion, a P/E ratio of 22.76, a P/E/G ratio of 0.87 and a beta of 0.51. The company has a 50-day moving average price of $27.67 and a two-hundred day moving average price of $24.56. Exelixis, Inc. has a 1 year low of $19.20 and a 1 year high of $36.17.

Exelixis (NASDAQ:EXEL - Get Free Report) last announced its quarterly earnings data on Tuesday, October 29th. The biotechnology company reported $0.40 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.36 by $0.04. Exelixis had a return on equity of 20.99% and a net margin of 22.43%. The company had revenue of $539.50 million for the quarter, compared to analysts' expectations of $490.31 million. During the same quarter in the prior year, the firm earned $0.10 earnings per share. Exelixis's revenue was up 14.3% compared to the same quarter last year. As a group, equities research analysts anticipate that Exelixis, Inc. will post 1.68 EPS for the current year.

Wall Street Analysts Forecast Growth

EXEL has been the subject of a number of recent analyst reports. Wells Fargo & Company upped their target price on Exelixis from $32.00 to $36.00 and gave the stock an "overweight" rating in a research report on Wednesday, October 30th. UBS Group started coverage on shares of Exelixis in a research report on Thursday, September 19th. They issued a "neutral" rating and a $30.00 price target on the stock. Stephens increased their price objective on shares of Exelixis from $23.00 to $29.00 and gave the stock an "equal weight" rating in a research report on Wednesday, October 30th. Oppenheimer reiterated an "outperform" rating and set a $29.00 target price on shares of Exelixis in a research note on Tuesday, July 30th. Finally, TD Cowen boosted their target price on shares of Exelixis from $27.00 to $34.00 and gave the stock a "buy" rating in a report on Monday, October 21st. One equities research analyst has rated the stock with a sell rating, five have issued a hold rating, fourteen have given a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat.com, Exelixis has an average rating of "Moderate Buy" and an average price target of $31.44.

Exelixis Profile

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.